Profile
Sector:
HealthcareCountry:
United KingdomIPO:
25 May 2018Website:
http://www.kiniksa.comNext earnings report:
31 October 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 04 Oct 2024 20:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
KNSA Latest News
Kiniksa Pharmaceuticals (KNSA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.
The consensus price target hints at a 30.1% upside potential for Kiniksa Pharmaceuticals (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.09.
– Abiprubart Phase 2b clinical trial in Sjögren's Disease to evaluate treatment response across biweekly and monthly subcutaneous administrations –
Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) will hold a conference call and live webcast on Tuesday, April 23, 2024 at 8:30 a.m. Eastern Time to discuss its first quarter 2024 financial results and recent portfolio execution.
The consensus price target hints at a 32.5% upside potential for Kiniksa Pharmaceuticals, Ltd. (KNSA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Does Kiniksa Pharmaceuticals, Ltd. (KNSA) have what it takes to be a top stock pick for momentum investors?
Kiniksa Pharmaceuticals, Ltd. (KNSA) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks.
Kiniksa Pharmaceuticals, Ltd. (KNSA) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.11 per share.
- 1(current)
What type of business is Kiniksa Pharmaceuticals?
Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was formerly known as Kiniksa Pharmaceuticals, Ltd and changed its name tpKiniksa Pharmaceuticals International, plc in June 2024. The company was incorporated in 2015 and is based in London, the United Kingdom.
What sector is Kiniksa Pharmaceuticals in?
Kiniksa Pharmaceuticals is in the Healthcare sector
What industry is Kiniksa Pharmaceuticals in?
Kiniksa Pharmaceuticals is in the Drug Manufacturers - Specialty & Generic industry
What country is Kiniksa Pharmaceuticals from?
Kiniksa Pharmaceuticals is headquartered in United Kingdom
When did Kiniksa Pharmaceuticals go public?
Kiniksa Pharmaceuticals initial public offering (IPO) was on 25 May 2018
What is Kiniksa Pharmaceuticals website?
https://www.kiniksa.com
Is Kiniksa Pharmaceuticals in the S&P 500?
No, Kiniksa Pharmaceuticals is not included in the S&P 500 index
Is Kiniksa Pharmaceuticals in the NASDAQ 100?
No, Kiniksa Pharmaceuticals is not included in the NASDAQ 100 index
Is Kiniksa Pharmaceuticals in the Dow Jones?
No, Kiniksa Pharmaceuticals is not included in the Dow Jones index
When was Kiniksa Pharmaceuticals the previous earnings report?
No data
When does Kiniksa Pharmaceuticals earnings report?
The next expected earnings date for Kiniksa Pharmaceuticals is 31 October 2024